Craft
  • Home
  •  / Sana Biotechnology
Sana Biotechnology

Sana Biotechnology

Pre-Clinical Phase Products

14

Q3, 2020

Market Capitalization

$1.2 B

2022-09-19

Sana Biotechnology Summary

Company summary

Overview
Sana Biotechnology is a company specializing in cell and gene therapy. It focuses on creating and delivering engineered cells as medicines for patients. The company deploys a platform that can repair and control genes in cells or replace any cell in the body.
Type
Public
Founded
2018
HQ
Seattle, WA, US | view all locations
Website
https://sana.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Steve Harr

    Steve Harr, President and Chief Executive Officer, Director

    • Robin Andrulevich

      Robin Andrulevich, Chief People Officer

    • Nate Hardy

      Nate Hardy, Chief Financial Officer

    • Christian Hordo

      Christian Hordo, Chief Business Officer

    Operating MetricsView all

    Pre-Clinical Phase Products

    14

    Q3, 2020

    LocationsView all

    3 locations detected

    • Seattle, WA HQ

      United States

      188 E Blaine St #400

    • Cambridge, MA

      United States

      300 Tech Square, 300 Technology Square #700

    • South San Francisco, CA

      United States

      1 Tower Pl #500

    Sana Biotechnology Financials

    Summary financials

    Net income (Q2, 2022)
    ($72.5M)
    Cash (Q2, 2022)
    $194.7M
    EBIT (Q2, 2022)
    ($72.9M)
    Enterprise value
    $1.2B

    Footer menu